Posted by Michael Wonder on 28 Oct 2020
TLV reconsiders the subsidy of Cosentyx
28 October 2020 - TLV starts a reconsideration to investigate the current subsidy status for Cosentyx.
The background to the review is that Cosentyx on 31 July 2020 received an extended indication and was approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6, who need systemic treatment.
